Clinical outcomes of bioresorbable versus durable polymercoated everolimus-eluting stents in real-world complex patients
| Autor: | Patrizia Presbitero, Paolo Pagnotta, Marco Araco, Omar A. Meelu, Federica Turati, Marco G. Mennuni, Gennaro Sardella, Giulio G. Stefanini, Bernhard Reimers, Elton Pllaha |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
Target lesion
medicine.medical_specialty XIENCE business.industry Everolimus eluting stent complex coronary artery disease complex patients everolimus-eluting stent SYNERGY 030204 cardiovascular system & hematology medicine.disease 03 medical and health sciences 0302 clinical medicine Internal medicine Cohort Durable polymer Propensity score matching Medicine 030212 general & internal medicine Myocardial infarction Cardiology and Cardiovascular Medicine business Mace Cohort study |
| Popis: | Aims The aim of this study was to evaluate the safety and efficacy profile of new-generation, SYNERGY everolimus-eluting stents (S-EES) as compared to XIENCE everolimus-eluting stents (X-EES) with a durable polymer coating in "complex patients". Methods and results We included 2,001 consecutive patients treated with S-EES (n=400) or X-EES (n=1,601) at two Italian centres between May 2013 and May 2015. We used propensity score matching to obtain two cohorts of patients with similar baseline risk profiles. Patients were stratified according to baseline complexity based on the EVOLVE II trial exclusion criteria. The primary outcome was major adverse cardiac events (MACE), defined as the composite of all-cause death, myocardial infarction (MI), and target lesion revascularisation (TLR), at one year. Among 391 matched pairs of patients treated with S-EES or X-EES, we identified 253 (63%) as complex. At one-year follow-up, among "complex" patients, MACE rates did not differ between the S-EES and X-EES groups (9.9% vs. 9.5%, p=0.830, HR 1.04, CI: 0.72-1.48). Similarly, death, MI, and TLR, stratified for complexity, were comparable between S-EES and X-EES treated patients at one year. Of note, no definite ST was observed in either the S-EES or the X-EES cohort. Conclusions New-generation S-EES with a bioresorbable polymer coating appear to be safe and effective irrespective of patient complexity as compared to X-EES. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|